mbx 2109
Peptideexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 10, 2021 (NCT05158335)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06531941 | Phase 2 | Oct 31, 2024 | MBX Biosciences |
| NCT06465108 | Phase 2 | Aug 8, 2024 | MBX Biosciences |
| NCT06496217 | Phase 1 | May 24, 2024 | MBX Biosciences |
| NCT05158335 | Phase 1 | Nov 10, 2021 | MBX Biosciences |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MBX Biosciences | For profit | 4 | 4 | 2 | 2021 |
1 organizations
Page 1 / 1